Deerfield Management Company, L.P.

Institutional investor · Portfolio as of Q4 2022

Q4 2022 biggest moves
  • AMLXAMLX

    Amylyx Pharmaceuticals

    New

    2.1% of portfolio

  • GILDGILD

    Gilead Sciences

    Sold out

    was 1.9% of portfolio

  • SPRYSPRY

    ARS Pharmaceuticals

    New

    2.0% of portfolio

  • BIIBBIIB

    Biogen

    Sold out

    was 1.8% of portfolio

95 changes in all

Top Holdings104 positions

Checking export access…
Activity:
NUVL
NUVLDelisted

NUVALENT INC

20M$595.3M12.3%——
6 qtrssince 2021-Q3
Increased
63
??
GLAUKOS CORPDelisted
Bond
271.8M$312.6M6.5%——
7 qtrssince 2021-Q2
Unchanged
0
??
INVITAE CORPDelisted
Bond
241.9M$190.8M4.0%——
10 qtrssince 2020-Q3
Increased
65
NBIX

Neurocrine Biosciences, Inc.

1.5M$180.7M3.7%$95.11+25.58%
8 qtrssince 2021-Q1
Unchanged
0
88.7M$165.4M3.4%——
4 qtrssince 2022-Q1
Unchanged
0
AHCO

AdaptHealth Corp.

7.6M$146.6M3.0%$23.56-18.43%
13 qtrssince 2019-Q4
Decreased
0
127.8M$118.3M2.4%——
3 qtrssince 2022-Q2
Unchanged
0
144.5M$114.6M2.4%——
8 qtrssince 2021-Q1
Unchanged
0
146M$112.2M2.3%——
1 qtr
New
78
VTRS

Viatris Inc.

10M$111.3M2.3%$14.06-32.58%
9 qtrssince 2020-Q4
Decreased
0
CPRX
CPRXDelisted

CATALYST PHARMACEUTICALS INC

5.9M$109.5M2.3%——
2 qtrssince 2022-Q3
Increased
61
??
NATERA INCDelisted
Bond
84.9M$108.1M2.2%——
7 qtrssince 2021-Q2
Increased
83
AMLX

Amylyx Pharmaceuticals, Inc.

2.7M$99.5M2.1%$36.950.00%
1 qtr
New
77
??
INSMED INCDelisted
Bond
102.7M$95.8M2.0%——
12 qtrssince 2020-Q1
Increased
62
98.4M$95.2M2.0%——
2 qtrssince 2022-Q3
Increased
58
??
NUVASIVE INCDelisted
Bond
97M$95.2M2.0%——
7 qtrssince 2021-Q2
Unchanged
0
AMED
AMEDDelisted

AMEDISYS INC

1.1M$94.9M2.0%——
3 qtrssince 2022-Q2
Increased
76
SPRY

ARS Pharmaceuticals, Inc.

11.1M$94.5M2.0%$8.530.00%
1 qtr
New
68
51.9M$79.4M1.6%——
10 qtrssince 2020-Q3
Unchanged
0
??
OAK STR HEALTH INCDelisted
Bond
100M$76M1.6%——
4 qtrssince 2022-Q1
Increased
64
$4.8B
AUM
104
Positions
Q4 2022
Filing
HI rating · 1.0/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2021-Q3$5,123,921,000-8.98360258545%
2021-Q4$4,767,581,000-6.95443977376%
2022-Q1$4,472,946,000-6.17996841585%
2022-Q2$4,848,381,0008.39346149048%
2022-Q3$5,023,740,0003.61685684355%
2022-Q4$4,831,008,337-3.83641794758%
Activity profile
$ moved · Q4'22
New22%Increased26%Decreased13%Exited40%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 1.7 years
<1Q13%1-4Q6%1-2Y34%2Y+48%

Deerfield Management Company, L.P. manages $4.8B across 104 positions as of Q4 2022. Top holdings: NUVL (12.3%), GLAUKOS CORP (6.5%), INVITAE CORP (4.0%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1/5.0.

Top holdings by portfolio weight

Total AUM$5B
NUVL12.32%
GLAUKOS CORP6.47%
INVITAE CORP3.95%
NBIX3.74%
SAREPTA THER3.42%
AHCO3.03%
IONIS PHARMA2.45%
TABULA RASA 2.37%
BROOKDALE SR2.32%
VTRS2.30%
Other2.27%

Portfolio allocation by GICS sector

Sectors3
Healthcare80.78%
Unknown18.38%
Industrials0.83%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare, Unknown
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L32
Conviction55
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
BCRXBCRXBioCryst Pharmaceuticals, Inc.
Q3 2025 → Q3 2026+10.8M shares+$87M
3Q
TNGXTNGXTango Therapeutics, Inc.
Q1 2026 → Q3 2026+2.3M shares+$103.5M
2Q
BMRNBMRNBioMarin Pharmaceutical Inc.
Q2 2026 → Q3 2026+1.2M shares+$73.4M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used